16/03/2022at 10:00

Gilde Healthcare closes oversubscribed fund

Dutch Gilde Healthcare has raised over EUR 500m in a new fund focused on the healthcare sector.

Jasper van Gorp, managing partner at Gilde Healthcare | Photo: Gilde Healthcare /PR

by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Dutch capital fund Gilde Healthcare has just closed its new private equity fund dubbed Gilde Healthcare Private Equity IV, raising EUR 517m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Million-dollar investment from Eir Ventures will bring Swedish cancer company to clinic
For subscribers
Bioinnovation Institute ramps up ambitions, wants twice as many companies under its wing
For subscribers
Novo CEO eyes cheap biotech market: "Of course the price matters, but there are other factors, too"
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis.

For subscribers

Pharma & biotech

Obesity drug hit makes Novo Nordisk more valuable than Nestle

For subscribers

Initial probes pointed to the contamination coming from the capsules containing Dicillin, or the drug's packaging | Foto: Lægemiddelstyrelsen / Pr

Other

Production at contaminated CMO continues – authorities deny further risks

For subscribers

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

For subscribers

California is taking a USD 50m step toward its ambition to make its own insulin products | Foto: George Frey/Reuters/Ritzau Scanpix

Pharma & biotech

California moves forward with making biosimilar insulin to Novo Nordisk product

For subscribers

Glenn Saldanha is chairman at the board of Glenmark | Foto: Danish Siddiqui/Reuters/Ritzau Scanpix

Pharma & biotech

Indian generic drugmaker to launch Leo Pharma copycat drug in US

For subscribers

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

The very top of the Danish drugmaker has only grown more distant to its own goal of ensuring 45% male/female representation across leadership teams.

For subscribers

Pharma & biotech

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

One of the Danish drugmaker’s partnered patient organizations did not disclose ties to Novo Nordisk in promotional material for obesity treatment.

For subscribers

Helge Lund, chairman at the board of directors at Novo Nordisk | Foto: Christopher Due Karlsson / Medwatch

Pharma & biotech

Novo Nordisk board discussed supply issues at every meeting in 2022

How to meet surging demand for some of the Danish drugmaker’s most popular drugs was amongst the most debated topics at the year’s board meetings, Chair Helge Lund says.

For subscribers

Gilde Healthcare closes oversubscribed fund

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Million-dollar investment from Eir Ventures will bring Swedish cancer company to clinic

Bioinnovation Institute ramps up ambitions, wants twice as many companies under its wing

Novo CEO eyes cheap biotech market: "Of course the price matters, but there are other factors, too"

Sign up for our newsletter

Front page now

Novo Nordisk enters collaboration with AI-driven drug discovery company

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Production at contaminated CMO continues – authorities deny further risks

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

California moves forward with making biosimilar insulin to Novo Nordisk product

Indian generic drugmaker to launch Leo Pharma copycat drug in US

Further reading

Less than one in five Novo Nordisk execs is a woman – chairman expects change over time

Novo Nordisk denies Danish stealth marketing, admits to carrying responsibility for grant usage

Novo Nordisk board discussed supply issues at every meeting in 2022

Jobs